LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

LLY

713.66

-0.21%↓

JNJ

153.02

+0.33%↑

ABBV

183.38

+0.57%↑

NVO

67.22

-1.34%↓

UNH

295.3

-0.39%↓

Search

Recursion Pharmaceuticals Inc

Suletud

SektorTervishoid

4.07 -1.69

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.06

Max

4.13

Põhinäitajad

By Trading Economics

Sissetulek

-24M

-202M

Müük

10M

15M

Aktsiakasum

-0.5

Kasumimarginaal

-1,373.259

Töötajad

800

EBITDA

-26M

-191M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+63.04% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-483M

1.8B

Eelmine avamishind

5.76

Eelmine sulgemishind

4.07

Uudiste sentiment

By Acuity

100%

0%

369 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

23. mai 2025, 20:33 UTC

Omandamised, ülevõtmised, äriostud

Salesforce in Talks to Buy Informatica, Bloomberg Reports, Citing Sources

23. mai 2025, 21:57 UTC

Kuumad aktsiad

Stocks to Watch: Apple, Booz Allen, Constellation Energy, Intuit -- WSJ

23. mai 2025, 21:15 UTC

Peamised uudised

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23. mai 2025, 21:04 UTC

Omandamised, ülevõtmised, äriostud

Real-Estate Broker Douglas Elliman Could See Takeover Battle After Report of Bid -- Barrons.com

23. mai 2025, 20:56 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Salesforce Back in Deal Talks With Informatica -- WSJ

23. mai 2025, 20:51 UTC

Peamised uudised

Boeing in Tentative Agreement to Pay $1.1 Billion to Avoid Trial for 737 MAX Crashes -- WSJ

23. mai 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

23. mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

23. mai 2025, 20:41 UTC

Peamised uudised

Stocks Fall on Tariff Broadside, After Week of Bond Market Agita -- WSJ

23. mai 2025, 20:28 UTC

Peamised uudised

Trump Threatens EU With 50% Tariffs, Takes Aim at Apple; Nasdaq Drops -- WSJ

23. mai 2025, 20:06 UTC

Peamised uudised

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 5th Update

23. mai 2025, 20:06 UTC

Omandamised, ülevõtmised, äriostud

Salesforce Stock Drops, Informatica Soars. A Deal May Be Back on the Table. -- Barrons.com

23. mai 2025, 19:50 UTC

Peamised uudised

Trump's Tariffs: Where Things Stand -- 16th Update

23. mai 2025, 19:28 UTC

Omandamised, ülevõtmised, äriostud

Trump on Truth Social: 'Bulk of That Investment Will Occur in the Next 14 Months'

23. mai 2025, 19:28 UTC

Omandamised, ülevõtmised, äriostud

Trump on Truth Social: 'This Will Be a Planned Partnership Between United States Steel and Nippon Steel'

23. mai 2025, 19:27 UTC

Omandamised, ülevõtmised, äriostud

Trump on Truth Social: 'Proud to Announce That, After Much Consideration and Negotiation, US Steel Will REMAIN in America'

23. mai 2025, 19:20 UTC

Market Talk

Crude Futures Post Modest Weekly Losses -- Market Talk

23. mai 2025, 19:18 UTC

Market Talk

U.S. Natural Gas Futures End Week Unchanged -- Market Talk

23. mai 2025, 18:57 UTC

Peamised uudised

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- 4th Update

23. mai 2025, 18:54 UTC

Peamised uudised

Trump Threatens Fresh Tariffs on EU, iPhones and Rival Devices -- Update

23. mai 2025, 18:53 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

McDonald's Bids Goodbye to CosMc's, Its Space Alien-Themed Spinoff -- WSJ

23. mai 2025, 18:52 UTC

Omandamised, ülevõtmised, äriostud

DDC Enterprise Issues 254,333 Class A Ordinary Shrs in Exchange for 21 BTC, Valued at About $2.28M in Current Market Price

23. mai 2025, 18:13 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

23. mai 2025, 18:13 UTC

Market Talk

Gold Trades Higher on Reminder of Risk -- Market Talk

23. mai 2025, 18:00 UTC

Peamised uudised

Apple's Stock Still Not Pricing in Trump's Demands - Heard on the Street -- WSJ

23. mai 2025, 17:51 UTC

Market Talk
Tulu

Workday Sees Higher Bar for Guidance -- Market Talk

23. mai 2025, 17:42 UTC

Peamised uudised

Dow Drops, Trump Threatens EU With 50% Tariffs, Takes Aim at Apple -- WSJ

23. mai 2025, 17:39 UTC

Market Talk

U.S. Oil Rig Count Falls to Lowest Level Since November 2021 -- Market Talk

23. mai 2025, 17:07 UTC

Peamised uudised

Trump's Tariffs: Where Things Stand -- 15th Update

23. mai 2025, 17:04 UTC

Market Talk
Tulu

Workday Appears to Have Upside Potential on Conservative Outlook -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Recursion Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

63.04% tõus

12 kuu keskmine prognoos

Keskmine 6.75 USD  63.04%

Kõrge 8 USD

Madal 3 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Recursion Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

1

Osta

4

Hoia

0

Müü

Tehniline skoor

By Trading Central

4.15 / 4.75Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

369 / 382 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.